BACKGROUND: There is controversy surrounding the value of the predicted postoperative diffusing capacity of lung for carbon monoxide (DLCOppo) in comparison to the forced expired volume in 1 s for prediction of pulmonary complications (PCs) after thoracic surgery. METHODS: Using a prospective database, we performed an analysis of 956 patients who had resection for lung cancer at a single institution. PC was defined as the occurrence of any of the following: atelectasis, pneumonia, pulmonary embolism, respiratory failure, and need for supplemental oxygen at hospital discharge. RESULTS: PCs occurred in 121 of 956 patients (12.7%). Preoperative chemotherapy (odds ratio 1.64, 95% confidence interval 1.06 -2.55, P ϭ 0.02, point score 2) and a lower DLCOppo (odds ratio per each 5% decrement 1.13, 95% confidence interval 1.06 -1.19, P Ͻ 0.0001, point score 1 per each 5% decrement of DLCOppo less than 100%) were independent risk factors for PCs. We defined 3 overall risk categories for PCs: low Յ10 points, 39 of 448 patients (9%); intermediate 11-13 points, 37 of 256 patients (14%); and high Ն14 points, 42 of 159 patients (26%). The median (range) length of hospital stay was significantly greater for patients who developed PCs than for those who did not: 12 (3-113) days vs 6 (2-39) days, P Ͻ 0.0001, respectively. Similarly, 30-day mortality was significantly more frequent for patients who developed PCs than for those who did not: 16 of 121 (13.2%) vs 6 of 835 (0.7%), P Ͻ 0.0001. CONCLUSIONS: These data show that PCs after thoracic surgery for lung cancer can be predicted with moderate accuracy based on DLCOppo and whether patients had chemotherapy. Forced expired volume in 1 s was not a predictor of
D
espite improvements in patient selection, anesthesia and surgical techniques, and intensive care management, clinically important pulmonary complications (PCs) occur in 10%-20% of patients after thoracic surgery. 1 PCs are more prevalent in this population than severe cardiovascular complications such as heart failure (3%-4%) or acute coronary syndromes (2%-3%) and have been identified as a leading cause of mortality after lung resections. 1, 2 The spectrum of PCs may range from atelectasis and pneumonia to acute lung injury (ALI), with the most severe form being acute respiratory distress syndrome (ARDS). 3 Previous reports examining risk factors for PCs after pulmonary resection have reported conflicting results regarding which preoperative clinical, spirometric, or laboratory data to include for risk estimation. The greater controversy is whether the frequently used forced expired volume in 1 s (FEV 1 ) is better able to predict PCs than the diffusing capacity of lung for carbon monoxide (DLCO). 4 -13 There is a growing body of evidence suggesting that the predicted postoperative DLCO (DLCOppo) is the stronger independent predictor of PCs. 10 -13 The evaluation of maximal oxygen consumption or 6-min walk testing of cardiopulmonary interaction was not considered here. The rationale for undertaking this study was to examine known clinical and frequently used spirometric characteristics reported to be associated with clinically important PCs in a large cohort of patients undergoing surgical resection for lung cancer, with a goal of developing a prediction rule so that future therapeutic strategies can be targeted to decrease hospital length of stay and health care costs.
METHODS
With IRB approval, the records of 956 patients who had undergone resection of primary lung cancer at our institution between 1992 and 2003 were retrospectively reviewed. These records were part of a continuing prospective database that included 1191 patients who participated in consecutive studies focused on cardiovascular complications and PCs after thoracic surgery. Patients who underwent surgery for tumors other than primary lung cancer were excluded (n ϭ 235). Neoadjuvant chemotherapy regimens used at our institution before surgery consisted of cisplatin and etoposide before 1995 and then mitomycin, vinblastine, and cisplatin until 2004. Carboplatin and paclitaxel (n ϭ 10) and other regimens (n ϭ 7) were used in patients treated at other institutions. Similarly, with the exception of 2 patients, radiotherapy before surgery was not used. Pulmonary function studies were performed after chemotherapy but before surgery. DLCO measurements were adjusted for hemoglobin. Postoperative PCs considered as study end points and recorded throughout the hospital stay were: respiratory failure requiring intensive care unit admission and/or intubation, pneumonia (new pulmonary infiltrate with fever treated with IV antibiotics), atelectasis requiring bronchoscopy (need determined by the surgical team), pulmonary embolism (diagnosed by computed tomographic scan and treated), and need for supplemental oxygen at hospital discharge. Pulmonary embolism was considered as an end point of pulmonary morbidity that may lead to oxygen requirement at hospital discharge. 7, 11 No patient had required use of oxygen before surgery. Transient hypoxemia and bronchospasm were not study end points. In contrast, patients who had cardiogenic causes of pulmonary edema, such as congestive heart failure, were excluded. Once discharged, patients were monitored by an investigator or research nurse for 30 days from the time of surgery for complications, intercurrent hospitalizations, or emergency department visits.
Standard anesthesia induction regimens, vecuronium for muscle relaxation, and maintenance of anesthesia using fentanyl and isoflurane in oxygen were used for all patients. Our standard of care is to use fluid restriction in the perioperative period. During 1-lung ventilation, a fraction of inspired oxygen of 1.0 and volume-controlled ventilation were used with a tidal volume of 6 -8 mL/kg, keeping peak inspiratory pressure Ͻ35 cm H 2 O. The respiratory rate was adjusted to maintain an end-tidal CO 2 Ͻ45 mm Hg. Postoperative analgesia was surgeon specific and consisted of IV morphine patient-controlled analgesia (n ϭ 133) or epidural fentanyl with bupivacaine 0.05% patientcontrolled analgesia (n ϭ 823). In all patients, pulmonary resection was performed via standard posterolateral thoracotomy using single-lung ventilation. It is our standard practice in patients who have anatomic lung resection to perform systemic mediastinal lymph node dissection. Corticosteroids are not given routinely during surgery.
Specific risk factors to be examined were defined a priori by searching the literature. Studies of PCs after anatomic pulmonary resection that included Ͼ200 patients were considered. 4 -13 Based on this review, the examined factors included volume of intraoperative fluid administered, extent of surgical resection, use of induction chemotherapy, laterality, and postoperative predicted lung function. Postoperative predicted lung function was calculated as follows: preoperative measured lung function ϫ (1 Ϫ number of segments resected/total number of segments). Wedge resection was defined as 1 segment. Data on patient characteristics, operative details, and postoperative recovery were collected in a prospective database approved by the IRB.
Statistical Analysis
Univariate characteristics between patients with and without PCs were compared using Student's t or 2 tests. A model was built using stepwise logistic regression to identify the subset of variables that jointly predicted postthoracic surgery PC risk. All variables whose univariate tests resulted in a P value Յ0.05 were considered in the model. There were 93 patients for whom DLCO measurements were not available. Concordance index (percent concordance) and area under the receiver operating characteristic (ROC) curve were computed as descriptive tools for measuring the discrimination of the model. The Hosmer-Lemeshow goodness-of-fit statistic was computed for examining the fit of the model. Internal validation of the predictive model was performed using jackknifing. We defined an integer-valued point scoring system as a proportional simplification of the logistic regression prediction function. We further classified patients as at low, intermediate, or high risk of PCs by partitioning into 3 groups, each with at least 3 contiguous point values. We evaluated the statistical significance of the grouped data for predicting risk of PCs using the Armitage test for trend in proportions and selected the most significant partition. We then reevaluated the P value using the Bonferroni correction for multiple testing (78 possible partitions).
Statistical significance of the grouping was confirmed using the Bonferroni procedure. SAS release 9.1.3 (SAS Institute, Cary, NC) was used for all analyses. Data are presented as mean value Ϯ sd or n (%). All statistical tests were 2-tailed, and P Ͻ 0.05 was regarded as significant.
RESULTS
Patient and operative characteristics are shown in Table 1 . Preoperative chemotherapy was given to 193 of 956 patients (20.2%) and consisted of mitomycin, vinblastine, and cisplatin in 155 patients and other regimens in 38 patients. One or more PCs occurred in 121 of 956 patients (12.7%) and consisted of respiratory failure in 23 (2.1%), pneumonia in 71 (7.4%), atelectasis in 15 (1.6%), pulmonary embolism in 12 (1.3%), and oxygen need on discharge in 24 (2.5%). Significant univariate associations with PCs were preoperative serum albumin level (P ϭ 0.03), preoperative chemotherapy, DLCO, and DLCOppo (Table 1) . Stepwise logistic regression analysis showed that preoperative chemotherapy (odds ratio 1.64, 95% confidence interval 1.06 -2.55, P ϭ 0.02, estimated coefficient 0.250) and a lower DLCOppo (odds ratio per each 5% decrement in DLCOppo 1.13, 95% confidence interval 1.06 -1.19, P Ͻ 0.0001, estimated coefficient 0.118) were independent risk factors for PCs. As a simple function of the model, we assigned point score 2 for history of preoperative chemotherapy and point score 1 per each 5% decrement of DLCOppo less than 100%. The predictive model based on these 2 variables had a concordance index of 0.63 and an area under the ROC curve of 0.63; the Hosmer-Lemeshow goodness-of-fit statistic suggested good calibration (P ϭ 0.43). Internal validation of the predictive model showed that the model is mildly overfitted (area under the jackknife-adjusted ROC curve ϭ 0.59). Figure 1 plots were observed and predicted probabilities of postoperative PCs were based on the computed point score from the final model. The partition of point scores into low-, intermediate-, and high-risk groups that was most strongly related to occurrence of PCs, as described in Methods, was 0 -10, 11-13, and 14 -19 points, respectively ( Table 2 ). The high-risk category included 159 patients with a 26% risk of PCs. This grouping was statistically significant at P Ͻ 0.0001 even after applying the Bonferroni correction for multiple testing.
We also created a stepwise logistic regression model including all variables whose univariate tests resulted in a P value Ͻ0.2 ( Table 1) . Only body mass index Ն30 (P ϭ 0.03) and history of hypertension (P ϭ 0.05) were statistically significant after adjusting for preoperative chemotherapy and DLCOppo. However, neither of the 2 factors added enough predictive power (concordance index of 0.64, and an area under the ROC curve of 0.65 and 0.64, respectively) to be included in our final model.
The median (range) length of hospital stay was significantly longer for patients who developed PCs than for those who did not: 12 (3-113) days vs 6 (2-39) days, P Ͻ 0.0001, t-test based on logarithm transformed data. Similarly, 30-day mortality was significantly more frequent for patients who developed PCs than for those who did not: 16 of 121 (13.2%) vs 6 of 835 (0.7%), P Ͻ 0.0001. The causes of mortality were respiratory failure/ARDS (n ϭ 11), multisystem organ failure (n ϭ 2), myocardial infarction (n ϭ 2), pulmonary embolism (n ϭ 2), and unknown (n ϭ 5).
DISCUSSION
The main findings of this study are that preoperative chemotherapy and a low DLCO independently contribute to the risk for clinically important postoperative PCs. A low DLCO was the strongest predictor, whereas FEV 1 was not an independent predictor at all. Using 2 easily available risk factors, we were able to develop a simple prediction rule and scoring system to estimate the likelihood of postoperative PC occurrence. Although DLCO in itself was highly associated with PCs, we used DLCOppo because it incorporates the extent of pulmonary resection with preoperative function. 10 -13 These risk factors are easily available before surgery, with DLCOppo contributing 1 point per each 5% decrement in DLCOppo from 100%, and preoperative chemotherapy 2 points in the point scoring system. For example, a patient with a history of preoperative chemotherapy exposure (2 points) and a DLCOppo of 50% ([100% Ϫ 50%]/5 ϭ 10 points) had a total of 12 points and a probability of 14% for developing postoperative PCs, compared with a similar patient without exposure to chemotherapy (10 points total) who had a 9% chance for PCs. We have previously reported that DLCOppo but not the FEV 1 was a predictor of PCs in a study of 300 patients designed to determine the effects of timing of smoking cessation on PCs. 11 Our results are likely explained by the fact that smokers are likely to have a greater incidence of primary lung cancer, require preoperative chemotherapy, and have significant reductions in preoperative diffusing capacity as a result of neoadjuvant chemotherapy and/or smoking.
14 Of the patients who received neoadjuvant chemotherapy, 80% were treated with mitomycin, a drug known to induce pulmonary toxicity.
14 Patients who developed PCs had twice the length of hospital stay and a Ͼ10-fold increase in 30-day mortality, with respiratory failure as the predominant cause.
DLCO estimates alveolar oxygen exchange, is generally not dependent on patient effort, and may be influenced by the patient's age, sex, height, and hemoglobin level. The measurement of DLCO before surgery is not universal. Of the 6 studies with Ն200 patients examining predictors of PCs where the FEV 1 but not DLCO was recorded, 3 showed (combined n ϭ 1219) that FEV 1 was an independent predictor 4 -6 and 3 (combined n ϭ 1506) did not. [7] [8] [9] In contrast, in studies that included both variables, DLCO was an independent predictor of PCs in all 4 (combined n ϭ 2471). 10 -13 Yano et al. 10 found that DLCO Ͻ70% of predicted was an independent predictor of non-lifethreatening as well as life-threatening complications in 291 patients after pulmonary resection. Using a continuous database over a span of Ͼ2 decades, Ferguson and Vigneswaran 13 retrospectively studied 1008 patients undergoing major anatomic pulmonary resection and reported that DLCOppo was the single strongest predictor of PCs and operative mortality in patients with or without chronic obstructive pulmonary disease. Brunelli et al. 12 retrospectively reviewed the records of 872 patients undergoing lung resection in 2 surgical units and found that DLCOppo Ͻ40% and age were independently associated with postoperative cardiopulmonary morbidity. In a study similar to ours, Licker et al. 15 concluded that FEV 1 Ͻ60% was the main predictor of PCs after resection for lung cancer, but DLCO was not available in the majority of patients.
The impact of neoadjuvant chemotherapy on morbidity and mortality after lung cancer surgery is controversial. 16 -20 In a retrospective study of 470 patients from our institution, Martin et al. 16 reported that right pneumonectomy, blood loss, and FEV 1 were independent predictors of combined cardiac, pulmonary, and other postoperative complications. Finally, in another large retrospective study of 758 patients, Matsubara et al. 18 showed that patients who received induction chemotherapy had a lower DLCO compared with those who did not. However, when examining risk factors for combined cardiopulmonary and other complications, the authors did not consider DLCO in their model. 18 ALI and ARDS are the most severe forms of lung injury and have been shown to occur in 2%-8% of patients after lung resection. 1, 3 In a recent study of 1428 patients undergoing lung cancer resection, we observed a 5.3% overall rate of lung injury and a 3.1% rate of severe injury in the form of ALI or ARDS. 3 The overall in-hospital mortality rate was 25% in the lung injury patients, compared with only 2.6% in the control group. Although larger intraoperative fluid administration was an independent predictor of ALI, DLCOppo was the strongest risk factor. Licker et al. 21 reviewed 879 patients who underwent pulmonary resection and showed in multivariate analysis that "excessive" fluid administration, high intraoperative ventilatory pressures, pneumonectomy, and preoperative alcohol abuse were independent risk factors for ALI. 21 Protective lung ventilation strategies have been shown to reduce inflammatory markers of barotrauma during thoracic surgery. 22 Although it is still controversial whether to use protective lung ventilation in all patients undergoing thoracic surgery regardless of risk for postoperative ALI, many would agree that patients with impaired lung function or those who have received chemotherapeutic drugs with potential pulmonary toxicity before surgery are a subset of patients at greater risk. Our study has several limitations. Epidural analgesia was used by most surgeons, in 833 of 956 cases (86%), and this may have affected the incidence of PCs. However, our observed incidence of PCs is consistent with nationally reported prospective data. 1 Because our study examined patients undergoing thoracotomy only, our conclusions may not apply to those undergoing thoracic surgery using minimally invasive techniques. The most significant single predictor of complications was DLCO, but there were 93 patients for whom DLCO measurements were not available. Although they comprise approximately 10% of the study population, this subgroup did not differ significantly from the remainder of the patients in terms of other covariates or incidence of complications. Furthermore, there was no combination of covariates that predicted DLCO accurately enough to impute missing DLCO values in order to include the additional cases in the model. Although the predictors in our study are highly significant, the overall accuracy of the prediction was moderate (area under the curve ϭ 0.63). As with other models produced by a single institution, ours may undergo performance drop-off when used in a new setting and therefore should have outside validation.
Clinical Implications and Conclusions
We present an easy prediction rule for estimating the risk of PCs after thoracic surgery using 2 independent predictors: decreasing DLCOppo and preoperative exposure to chemotherapy. To the best of our knowledge, this is the largest study combining clinical and standard pulmonary function characteristics in designing a practical rule to predict PCs after thoracic surgery. Several authors have proposed combining cardiovascular, pulmonary, and other factors to estimate risk of overall morbidity and mortality after pulmonary resection. 24 -26 In contrast, our analysis was focused on defining risk factors associated with pulmonary morbidity. Using this scoring system, we were able to establish low-, intermediate-, and high-risk categories for postoperative PCs, providing a very simple scoring system. Postoperative PCs may lead to ALI and/or ARDS, which are causes of morbidity and mortality after pulmonary resections for lung cancer. 1, 3 Because it is not practical to recommend withholding preoperative chemotherapy, other proven strategies can be considered to reduce PCs. Using the proposed prediction rule, the high-risk group should undergo preoperative interventions such as pulmonary rehabilitation, smoking cessation, and pharmacological prophylaxis as clinically needed. Whether one can justify delaying surgery to achieve these measures in the very high-risk group is not known. These patients should receive protective lung ventilation and fluid restriction strategies during surgery. 11,19 -21,27,28 Postoperatively, proven strategies to reduce PCs such as lung expansion interventions should be used. 26 Although the low-risk group may not require these interventions, for high-and intermediate-risk patients, risk-benefit analyses for potential prevention or therapeutic strategies, including delaying surgery, would provide evidence-based data to develop a strategy to minimize related adverse events and costs.
